Predicting unreported clinical trial efficacy using an ex-vivo tumor platform: Pembrolizumab+pt+5-FU vs. extreme in recurrent head and neck squamous cell carcinoma.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2018
This article has no abstract
Epistemonikos ID: 44b092d628f9a168482a4af18713834f59744769
First added on: Feb 10, 2025